A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

NCT05193409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Social Anxiety Disorder

Interventions

DRUG: 225 mg BNC210
DRUG: 675 mg BNC210
DRUG: Placebo

Sponsor

Bionomics Limited